Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2017-12-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司产品取得欧盟CE认证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the company's wholly owned subsidiary obtaining EU CE certification for a medical product. It includes product details, certification dates, and a brief impact statement. There is no financial data, no mention of a report or filing, and the document length is only 585 characters. It is clearly an announcement of a regulatory or product certification event, not a financial report or management information. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2017-12-05 Chinese
关于全资子公司医疗器械注册证变更的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a change in the medical device registration certificate for a subsidiary's product. It details the approval of a change by the National Medical Products Administration (China's regulatory body for medical devices), specifying the product and the change in applicable equipment models. The document does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about product registration changes, not a financial report or management discussion. The document length is short (799 characters), and it is an announcement of a regulatory approval/change. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-12-04 Chinese
关于对深圳证券交易所问询函的回复暨媒体报道的澄清公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. responding to an inquiry letter from the Shenzhen Stock Exchange regarding discrepancies in IPO prospectus data and clarifying media reports about litigation involving the controlling shareholder. It addresses specific questions about data differences in IPO filings and litigation status, providing detailed explanations and assurances about the accuracy and completeness of disclosed information. The document does not contain financial statements or detailed financial data but serves as a regulatory response and clarification to the exchange and public. It is relatively short (2706 characters) and focuses on regulatory compliance and disclosure clarifications rather than presenting a full report or financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2017-11-27 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations of Shenzhen BGI Genomics Co., Ltd. It details the stock price drop over specific dates, the company's investigation and response to media reports, confirmation of no undisclosed material information, and risk warnings related to the company's business environment. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document serves as a regulatory disclosure about stock trading anomalies and risk factors, typical of a Regulatory Filing (RNS). The document length is short (2163 characters), and it is not a report or presentation but an announcement of a specific event and related clarifications.
2017-11-27 Chinese
关于全资子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a medical device registration certificate by a wholly-owned subsidiary. It includes details about the certificate, product description, and potential impact on the company. The document is short (877 characters) and serves as a formal notification rather than a detailed report or financial statement. There is no indication of financial results, management discussion, or regulatory certifications. It is an official announcement of a regulatory approval related to the company's product, which fits best under general regulatory announcements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-11-22 Chinese
股票停牌核查情况暨复牌公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding the suspension and resumption of trading of the company's stock due to abnormal price fluctuations. It includes details about the investigation conducted during the suspension, confirmation of no undisclosed material information, and risk warnings related to the company's business environment. The document does not contain financial statements or detailed financial data, nor is it a report like an annual or interim report. It is a regulatory announcement about stock trading status and related disclosures. Therefore, it fits best under Regulatory Filings (RNS). The document length is 2365 characters, which is relatively short and consistent with an announcement rather than a full report.
2017-11-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.